- Trials with a EudraCT protocol (297)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
297 result(s) found for: Relapsing-remitting.
Displaying page 3 of 15.
EudraCT Number: 2008-004579-22 | Sponsor Protocol Number: GAM-25 | Start Date*: 2008-10-14 |
Sponsor Name:Octapharma AG | ||
Full Title: A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam ... | ||
Medical condition: Subjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-000653-32 | Sponsor Protocol Number: CFTY720DDE17 | Start Date*: 2012-06-27 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START) | |||||||||||||
Medical condition: Conduction abnormalities in patients with relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004483-38 | Sponsor Protocol Number: TMP001_MS | Start Date*: 2015-07-16 | |||||||||||
Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) | |||||||||||||
Full Title: TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial | |||||||||||||
Medical condition: Patients with defined diagnosis of relapsing-remitting multiple sclerosis and at least 1 documented relapse during the previous year OR at least 2 documented relapses during the previous 2 years. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000303-21 | Sponsor Protocol Number: BIIT0115 | Start Date*: 2015-06-24 | |||||||||||
Sponsor Name:Biogen Idec Italia S.r.l. | |||||||||||||
Full Title: A Phase IV, interventional, multicenteR, double-blind, randomized, placebo-controlled study tO explore the onset of efficacy on Magnetic resonance disease activity of BG00012 (dimethyl fumarate) in... | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011585-28 | Sponsor Protocol Number: BGC20-0134-02 | Start Date*: 2009-10-08 | |||||||||||
Sponsor Name:BTG International Ltd | |||||||||||||
Full Title: A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS) | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) FR (Ongoing) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010788-18 | Sponsor Protocol Number: CAMMS03409 | Start Date*: 2009-07-01 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) AT (Completed) PL (Completed) CZ (Completed) NL (Completed) DK (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012500-11 | Sponsor Protocol Number: 205MS301 | Start Date*: 2010-04-12 | |||||||||||
Sponsor Name:Biogen Idec Ltd | |||||||||||||
Full Title: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) FR (Completed) DE (Completed) CZ (Completed) HU (Completed) FI (Completed) SE (Completed) ES (Completed) GB (Completed) GR (Completed) IT (Completed) DK (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001161-42 | Sponsor Protocol Number: 205-MS-201 | Start Date*: 2006-08-29 | |||||||||||
Sponsor Name:Biogen Idec Ltd | |||||||||||||
Full Title: Multicentre, double-blind, placebo-controlled, dose-ranging study to determine the safety and efficacy of daclizumab HYP (DAC HYP) as a monotherapy treatment in subjects with relapsing-remitting mu... | |||||||||||||
Medical condition: Multiple sclerosis (MS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Prematurely Ended) DE (Prematurely Ended) HU (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004431-24 | Sponsor Protocol Number: 67896153MSC3001 | Start Date*: 2022-11-03 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Vers... | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) SE (Completed) IT (Prematurely Ended) FR (Ongoing) BE (Completed) PL (Completed) CZ (Completed) BG (Completed) HU (Prematurely Ended) PT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005550-57 | Sponsor Protocol Number: GA-MS-302 | Start Date*: 2012-05-15 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd. | |||||||||||||
Full Title: A multinational, multicenter, randomized, parallel group, double blind, placebo controlled study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, saf... | |||||||||||||
Medical condition: Relapsing-remitting Multiple sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015815-42 | Sponsor Protocol Number: MS-LAQ-302E | Start Date*: 2010-03-12 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd | |||||||||||||
Full Title: A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laqu... | |||||||||||||
Medical condition: Laquinimod is developed for the treatment of relapsing remitting multiple sclerosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003176-39 | Sponsor Protocol Number: 205MS303 | Start Date*: 2013-05-31 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Prematurely Ended) CZ (Completed) HU (Completed) PL (Completed) SE (Completed) ES (Completed) IE (Prematurely Ended) GB (Completed) FI (Prematurely Ended) GR (Completed) FR (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003481-25 | Sponsor Protocol Number: DIMAT-MS | Start Date*: 2015-05-13 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis | |||||||||||||
Medical condition: relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014339-19 | Sponsor Protocol Number: ONO-4641POU006 | Start Date*: 2010-03-26 | |||||||||||
Sponsor Name:ONO Pharmaceutical Co., Ltd. | |||||||||||||
Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001629-25 | Sponsor Protocol Number: CAIN457B2201E1 | Start Date*: 2012-01-10 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open label extension study to evaluate the safety, tolerability and efficacy of AIN457 in patients with relapsing-remitting multiple sclerosis | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005082-13 | Sponsor Protocol Number: 101MS328 | Start Date*: 2013-04-02 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Scle... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004602-97 | Sponsor Protocol Number: VITADEM | Start Date*: 2013-01-11 | |||||||||||
Sponsor Name:Javier Olascoaga Urtaza | |||||||||||||
Full Title: ?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial? | |||||||||||||
Medical condition: RELAPSING-REMITING MULTIPLE SCLEROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009503-19 | Sponsor Protocol Number: TYS-IMA-08-11 | Start Date*: 2010-07-20 | |||||||||||
Sponsor Name:Biogen Idec International GmbH | |||||||||||||
Full Title: A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002096-27 | Sponsor Protocol Number: CFTY720D2309 | Start Date*: 2008-09-10 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) AT (Completed) LT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000708-26 | Sponsor Protocol Number: CFTY720DIT15T | Start Date*: 2016-09-23 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Evaluation of clinical response in relation to the immunological status change in RRMS patients treated with Gilenya (fingolimod) for 12 months. | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
